Drug-releasing sinus stent

• US 20070014830A1
• Filed: 06/08/2005
• Published: 01/18/2007
• Est. Priority Date: 06/08/2005
• Status: Abandoned Application

• Current Assignee: Medtronic Xomed Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Xomed Incorporated (Medtronic Plc)
• Inventors: Hissong, James, Bachert, Claus, Watelet, Jean-Baptiste, Tijsma, Edze
• Application Number:
  US11/147,929
• Publication Number:
  US 20070014830A1
• Time in Patent Office: Days
• US Class Current: 424/426
• CPC Class Codes: A61F 2/186 Nose parts
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61K 31/65 Tetracyclines

Abstract

The present invention relates to a stent, adapted for deployment in a nasal sinus, comprising a matrix metalloproteinase-inhibiting substance and capable of locally releasing in a controlled manner a therapeutically effective amount of said matrix metalloproteinase-inhibiting substance. The invention further relates to a method for treatment of a diseased or damaged sinus mucosal tissue in a patient, said method comprising introducing into the sinus of said patient a stent comprising a matrix metalloproteinase-inhibiting substance.

Claims

1. A stent, adapted for deployment in a paranasal sinus and/or nasal passageway, comprising a matrix metalloproteinase-inhibiting substance and capable of locally releasing in a controlled manner a therapeutically effective amount of said matrix metalloproteinase-inhibiting substance.

2. The stent according to claim 1 wherein said nasal sinus is the ethmoid sinus and/or frontal sinus.

3. The stent according to claim 1, wherein said matrix metalloproteinase-inhibiting substance inhibits matrix metalloproteinase-9 and/or matrix metalloproteinase-7.

4. The stent according to claim 1, wherein said matrix metalloproteinase-inhibiting substance is comprised in a surface coating of said stent.

5. The stent according to claim 4, wherein said surface coating comprises a polymeric carrier comprising poly (caprolactone), poly (lactic acid), poly (ethylene-vinyl acetate), a copolymer of caprolactone and lactic acid, poly(alpha-hydroxy esters), polyacrylates, ethylene vinyl acetate copolymer or silicone.

6. The stent according to claim 1, wherein said stent consists of a sheath forming a hollow body and at least two apertures, said sheath being composed of at least one layer, and wherein said at least one layer comprises said matrix metalloproteinase-inhibiting substance.

7. The stent according to claim 1, wherein said matrix metalloproteinase-inhibiting substance is doxycycline and/or TIMP-1.

8. The stent according to claim 1, further comprising at least one pharmaceutical agent involved in remodeling processes.

9. A method for treatment of a diseased or damaged (para)nasal mucosal tissue in a patient, said method comprising introducing into the paranasal sinus and/or nasal passageway of said patient a stent comprising a matrix metalloproteinase-inhibiting substance and capable of locally releasing in a controlled manner a therapeutically effective amount of said matrix metalloproteinase-inhibiting substance.

10. The method according to claim 9, wherein said sinus mucosal tissue is ethmoid sinus mucosal tissue and/or frontal sinus mucosal tissue.

11. The method according to claim 9, wherein said matrix metalloproteinase-inhibiting substance inhibits matrix metalloproteinase-9 and/or matrix metalloproteinase-7.

12. The method according to claim 9, wherein said matrix metalloproteinase-inhibiting substance is doxycycline and/or TIMP-1.

13. A method for treatment of a diseased or damaged sinus mucosal tissue in a patient, said method comprising:

measuring the preoperative concentration of matrix metalloproteinase-9 in nasal fluid;

comparing said concentration with normal baseline levels obtained by measuring the concentration of nasal fluid matrix metalloproteinase-9 in individuals without previous sinus surgery;

optionally performing paranasal sinus surgery on said patient, and

introducing into the paranasal sinus and/or nasal passageway of said patient a stent comprising a matrix metalloproteinase-inhibiting substance and capable of locally releasing in a controlled manner a therapeutically effective amount of said matrix metalloproteinase-inhibiting substance, in case said preoperative concentration of matrix metalloproteinase-9 in the nasal fluid of said patient is above said baseline levels.

14. The method according to claim 13, wherein said sinus mucosal tissue is ethmoid sinus mucosal tissue and/or frontal sinus mucosal tissue and/or nasal passageway tissue.

15. The method according to claim 13, wherein said matrix metalloproteinase-inhibiting substance inhibits matrix metalloproteinase-9 and/or matrix metalloproteinase-7.

16. The method according to claim 13, wherein said substance is doxycycline and/or TIMP-1.